Kennedy’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Kennedy’s Disease Market Outlook
Thelansis’s “Kennedy’s Disease Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Kennedy’s Disease treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Kennedy’s Disease Overview
Kennedy’s
disease, called bulbospinal muscular atrophy (BSMA), is a rare genetic disorder
following an X-linked recessive inheritance pattern characterized by the
degeneration of motor neurons leading to muscle wasting in the proximal and
bulbar regions. BSMA is caused by an unstable expansion of a CAG triplet repeat
(40-62 repeats) in exon 1 of the androgen receptor (AR) gene located on
chromosome Xq11-12. The onset of symptoms typically occurs between the ages of
30 and 60 years, and initial clinical manifestations may include tremors,
muscle cramps, twitching, fatigue, and slurred speech. With disease
progression, patients may experience weakness and wasting of the limb and
bulbar muscles, resulting in dysarthria, dysphonia, hanging jaw, tongue
wasting, chewing difficulty, and impaired mobility. The disease may be
misdiagnosed initially as hereditary spastic paraplegia, spinocerebellar
ataxia, other motor neuron diseases, myopathies, neuropathies, or cervical
spondylosis. The progression of BSMA is slow, with only one-third of patients
requiring a wheelchair 20 years after diagnosis. The prognosis for BSMA is
generally favorable, with only a slight decrease in life expectancy.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment